Abstract
Arterial stiffness is the most important cause of increasing systolic and pulse pressure, and for decreasing diastolic pressure with ageing. Many measures can be applied to quantify arterial stiffness, but all are approximations only, on account of the nonhomogenous structure of the arterial wall, its variability in different locations, at different levels of distending pressure, and with changes in smooth muscle tone. This article summarizes those indices with a focus on newer non-invasive methods and provides an overview of physiological, pathological and pharmacological influences on arterial hemodynamics. In the near future, the ability to detect and monitor subclinical arterial damage will improve cardiovascular risk stratification and act as a better guide in assessing the efficacy of therapeutic interventions than monitoring blood pressure alone. However, large-scale clinical trials are needed to prove the hypothesis that treatment of these new therapeutic targets will translate into clinical benefit, expressed in cardiovascular events or even mortality.
Keywords: arterial stiffness, cardiovascular drugs, arterial hemodynamics, arterial physiology
Current Pharmaceutical Design
Title: Arterial Stiffness and Cardiovascular Drugs
Volume: 9 Issue: 13
Author(s): Thomas Weber, Johann Auer, Geza Eisserer, Robert Berent, Bernd Eber and Michael F. O´Rourke
Affiliation:
Keywords: arterial stiffness, cardiovascular drugs, arterial hemodynamics, arterial physiology
Abstract: Arterial stiffness is the most important cause of increasing systolic and pulse pressure, and for decreasing diastolic pressure with ageing. Many measures can be applied to quantify arterial stiffness, but all are approximations only, on account of the nonhomogenous structure of the arterial wall, its variability in different locations, at different levels of distending pressure, and with changes in smooth muscle tone. This article summarizes those indices with a focus on newer non-invasive methods and provides an overview of physiological, pathological and pharmacological influences on arterial hemodynamics. In the near future, the ability to detect and monitor subclinical arterial damage will improve cardiovascular risk stratification and act as a better guide in assessing the efficacy of therapeutic interventions than monitoring blood pressure alone. However, large-scale clinical trials are needed to prove the hypothesis that treatment of these new therapeutic targets will translate into clinical benefit, expressed in cardiovascular events or even mortality.
Export Options
About this article
Cite this article as:
Weber Thomas, Auer Johann, Eisserer Geza, Berent Robert, Eber Bernd and O´Rourke F. Michael, Arterial Stiffness and Cardiovascular Drugs, Current Pharmaceutical Design 2003; 9 (13) . https://dx.doi.org/10.2174/1381612033455080
DOI https://dx.doi.org/10.2174/1381612033455080 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets Therapeutic Potential of P2X7 Purinergic Receptor Modulation in the Main Organs Affected by the COVID-19 Cytokine Storm
Current Pharmaceutical Design Factors Associated with Mortality in Patients with Coronavirus Disease (COVID-19) in Babol, North of Iran
Infectious Disorders - Drug Targets Premature Adrenarche and its Association with Cardiovascular Risk in Females
Current Pharmaceutical Design Urotensin-II Receptor Antagonists
Current Medicinal Chemistry Association of Nocturnal Heart Rate with White Matter Hyperintensity Burden in Cerebral Small Vessel Disease Patients
Current Neurovascular Research The Role of the Brain Renin-Angiotensin System in Neurodegenerative Disorders
Current Alzheimer Research Food-Derived Peptides and Intestinal Functions
Current Pharmaceutical Design Pharmacological Agents and Potential New Therapies in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Lipid Management and Peripheral Arterial Disease
Current Drug Targets Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective
Current Drug Targets - Cardiovascular & Hematological Disorders Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry The Meaning of Different Forms of Structural Myocardial Injury, Immune Response and Timing of Infarct Necrosis and Cardiac Repair
Current Vascular Pharmacology The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro- and Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach
Current Diabetes Reviews Allergen-Induced Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epigenetic Regulation in Particulate Matter-Mediated Cardiopulmonary Toxicities: A Systems Biology Perspective
Current Pharmacogenomics and Personalized Medicine Sustained ELABELA Gene Therapy in High-salt Diet-induced Hypertensive Rats
Current Gene Therapy Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Polyphenols, Antioxidants and the Sympathetic Nervous System
Current Pharmaceutical Design In-Vivo Gene Delivery by Sonoporation: Recent Progress and Prospects
Current Gene Therapy